FinancialTOHO HOLDINGS CO.
Summary of Consolidated Financial Results: First Half of Fiscal Year Ending March 2014
15 pages~25 min full read
TOHO HOLDINGS CO., LTD. reported net sales of 579,175 million yen for the first half of fiscal year 2014, a 4.1% increase year-on-year.
See it on page 1Profitability declined across all major metrics, with operating income falling 10.3% to 5,298 million yen, ordinary income dropping 2.9% to 8,387 million yen, and net income decreasing 4.5% to 4,914 million yen.
See it on page 9The pharmaceutical wholesaling segment remains the company's primary revenue driver, contributing 556,364 million yen in sales.
See it on page 4The dispensing pharmacy and site management organization (SMO) segments achieved growth in both sales and segment income during the period.
See it on page 4A change in accounting methodology was implemented to record non-deductible consumption taxes as SG&A expenses rather than non-operating expenses, with prior-year figures retroactively adjusted.
See it on page 6As of September 30, 2013, the company held total assets of 557,031 million yen and total net assets of 141,175 million yen.
See it on page 7Operating activities resulted in a cash outflow of 20,695 million yen, primarily driven by fluctuations in trade payables and receivables.
See it on page 5The consolidated financial results for the first half of the fiscal year ending March 2014 reflect the performance of TOHO HOLDINGS CO., LTD. within the Japanese pharmaceutical and healthcare sector. The primary objective of this report is to disclose operational and financial outcomes for the six-month period ending September 30, 2013, while providing context for management’s medium-term strategy, "Total Commitment to Good Health 14-16."
During this period, the company achieved net sales of 579,175 million yen, representing a 4.1% increase compared to the previous year. Despite this growth in top-line revenue, profitability metrics declined: operating income fell by 10.3% to 5,298 million yen, ordinary income decreased by 2.9% to 8,387 million yen, and net income dropped by 4.5% to 4,914 million yen. The pharmaceutical wholesaling segment remained the primary revenue driver, contributing 556,364 million yen in sales, while the dispensing pharmacy and site management organization (SMO) segments demonstrated notable year-on-year growth in both sales and segment income.
A significant methodological change was implemented in the first quarter of the fiscal year regarding the accounting treatment of non-deductible consumption taxes. Previously classified as non-operating expenses, these costs are now recorded as selling, general, and administrative (SG&A) expenses to better reflect the growing scale of the dispensing pharmacy business and anticipated tax rate adjustments. Comparative figures from the prior year were retroactively reclassified to ensure consistency.
The company’s financial position as of September 30, 2013, showed total assets of 557,031 million yen and total net assets of 141,175 million yen. Cash flow from operating activities resulted in an outflow of 20,695 million yen, largely influenced by changes in trade payables and receivables. Management maintained its full-year performance projections, anticipating continued growth in line with the established medium-term plan.
